{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:26:19Z","timestamp":1760055979401,"version":"build-2065373602"},"reference-count":75,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Despite significant progress in oncology therapeutics, cancer remains a leading cause of\nmortality worldwide. Chronic myeloid leukemia, which accounts for 15% of all adult leukemia\ncases, is characterized by chromosomal abnormalities involving the fusion of the Bcr and Abl genes\nto form the Bcr-Abl oncogene. Current drug treatment of the disease involves the use of Bcr-Abl\ntyrosine kinase inhibitors belonging to the first, second, and third generations. However, the toxicity\nand resistance associated with the use of imatinib, a first-generation Bcr-Abl inhibitor, in cases\nwhere the T315I mutation exists, necessitates the need for new tyrosine kinase inhibitors. This review\nfocuses on recent synthetic compounds that exhibit potential as inhibitors of the Bcr-Abl protein\nwhich could be utilized in chemotherapy. Herein, we evaluated and summarized 36 studies\npublished in the last few years that reported on newly synthesized and biologically evaluated novel\nsmall molecules with different heterocyclic scaffolds as Bcr-Abl tyrosine kinase inhibitors. The\nintricacy of the structure of newly synthesized compounds and the fact that each compound contains\nmore than one scaffold makes it difficult to infer the potentially active core or scaffold. However,\ninvestigating different combined scaffolds enhances the chance of successfully developing\nnovel drug candidates. Overall, the information provided in this review can be beneficial to researchers\nwith an interest in chronic myeloid leukemia and tyrosine kinase inhibitors.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115734064311341240929175508","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T07:31:22Z","timestamp":1728891082000},"page":"646-665","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Heterocyclic Compounds as Bcr-Abl Tyrosine Kinase Inhibitors Against Chronic Myeloid Leukemia"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-661X","authenticated-orcid":true,"given":"Sarah","family":"Gado","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, 06100, Ankara, Turkey"},{"name":"Graduate School of Health Sciences, Ankara University, 06110 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5423-4633","authenticated-orcid":true,"given":"Mohammed Al-Kassim","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, 06100, Ankara, Turkey"},{"name":"Graduate School of Health Sciences, Ankara University, 06110 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6209-0361","authenticated-orcid":true,"given":"Mehmet Murat","family":"Kisla","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, 06100, Ankara, Turkey"},{"name":"Graduate School of Health Sciences, Ankara University, 06110 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5898-9988","authenticated-orcid":true,"given":"Zeynep","family":"Ates-Alagoz","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, 06100, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"S362","DOI":"10.1016\/j.annonc.2021.08.282","volume":"32","author":"Yin L.","year":"2021","unstructured":"Yin L.; Yao Z.; Wang Y.; Huang Y-H.; Mazuranic M.; Yin A.; 4MO Preclinical evaluation of novel CDK4\/6 inhibitor GLR2007 in breast and lung cancer models. Ann Oncol  2021,32,S362","journal-title":"Ann Oncol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung H.","year":"2021","unstructured":"Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2021,71(3),209-249","journal-title":"CA Cancer J Clin"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-23-0411","volume":"21","author":"Brown J.S.","year":"2023","unstructured":"Brown J.S.; Amend S.R.; Austin R.H.; Gatenby R.A.; Hammarlund E.U.; Pienta K.J.; Updating the definition of cancer. Mol Cancer Res  2023,21(11),1142-1147","journal-title":"Mol Cancer Res"},{"key":"ref=4","first-page":"2","volume":"5","author":"Taverna S.","year":"2017","unstructured":"Taverna S.; Corrado C.; Natural compounds: Molecular weapons against Leukemia\u2019s. J Leuk (Los Angel)  2017,5(226),2","journal-title":"J Leuk (Los Angel)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","volume":"834","author":"Lee Y.T.","year":"2018","unstructured":"Lee Y.T.; Tan Y.J.; Oon C.E.; Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol  2018,834,188-196","journal-title":"Eur J Pharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/bcpt.12313","volume":"116","author":"R\u00f8sland G.V.","year":"2015","unstructured":"R\u00f8sland G.V.; Engelsen A.S.T.; Novel points of attack for targeted cancer therapy. Basic Clin Pharmacol Toxicol  2015,116(1),9-18","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12288-013-0316-6","volume":"30","author":"Brahmbhatt M.M.","year":"2014","unstructured":"Brahmbhatt M.M.; Trivedi P.J.; Patel D.M.; Shukla S.N.; Patel P.S.; Location of the BCR\/ABL fusion genes on both chromosomes 9 in Ph negative young chronic myeloid leukemia patients: An indian experience. Indian J Hematol Blood Transfus  2014,30,241-246","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"155161","DOI":"10.1016\/j.prp.2024.155161","volume":"254","author":"El-Tanani M.","year":"2024","unstructured":"El-Tanani M.; Nsairat H.; Matalka I.I.; Lee Y.F.; Rizzo M.; Aljabali A.A.; Mishra V.; Mishra Y.; Hromi\u0107-Jahjefendi\u0107 A.; Tambuwala M.M.; The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia. Pathol Res Pract  2024,254,155161","journal-title":"Pathol Res Pract"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5306\/wjco.v12.i2.69","volume":"12","author":"Sampaio M.M.","year":"2021","unstructured":"Sampaio M.M.; Santos M.L.C.; Marques H.S.; Gon\u00e7alves V.L.S.; Ara\u00fajo G.R.L.; Lopes L.W.; Apolonio J.S.; Silva C.S.; Santos L.K.S.; Cuzzuol B.R.; Guimar\u00e3es Q.E.S.; Santos M.N.; de Brito B.B.; da Silva F.A.F.; Oliveira M.V.; Souza C.L.; de Melo F.F.; Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review. World J Clin Oncol  2021,12(2),69-94","journal-title":"World J Clin Oncol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s12185-022-03451-4","volume":"117","author":"Sun H.","year":"2023","unstructured":"Sun H.; Yan Z.; Zhang S.; Three atypical BCR\/ABL transcripts detected simultaneously in a Philadelphia-positive acute lymphoblastic leukemia patient showing resistance to tyrosine kinase inhibitors. Int J Hematol  2023,117(1),134-136","journal-title":"Int J Hematol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjh.12301","volume":"161","author":"Nacheva E.P.","year":"2013","unstructured":"Nacheva E.P.; Grace C.D.; Brazma D.; Gancheva K.; Howard-Reeves J.; Rai L.; Gale R.E.; Linch D.C.; Hills R.K.; Russell N.; Burnett A.K.; Kottaridis P.D.; Does BCR\/ABL1 positive acute myeloid leukaemia exist? Br J Haematol  2013,161(4),541-550","journal-title":"Br J Haematol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/6707506","volume":"2019","author":"Mariotti B.","year":"2019","unstructured":"Mariotti B.; Meconi F.; Palmieri R.; De Bellis E.; Lavorgna S.; Ottone T.; Martini V.; Lo-Coco F.; Cicconi L.; Acute myeloid leukemia with concomitant Bcr-Abl and NPM1 mutations. Case Rep Hematol  2019,2019,1-4","journal-title":"Case Rep Hematol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"Deininger M.W.","year":"2020","unstructured":"Deininger M.W.; Shah N.P.; Altman J.K.; Berman E.; Bhatia R.; Bhatnagar B.; DeAngelo D.J.; Gotlib J.; Hobbs G.; Maness L.; Mead M.; Metheny L.; Mohan S.; Moore J.O.; Naqvi K.; Oehler V.; Pallera A.M.; Patnaik M.; Pratz K.; Pusic I.; Rose M.G.; Smith B.D.; Snyder D.S.; Sweet K.L.; Talpaz M.; Thompson J.; Yang D.T.; Gregory K.M.; Sundar H.; Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw  2020,18(10),1385-1415","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"Druker B.J.","year":"1996","unstructured":"Druker B.J.; Tamura S.; Buchdunger E.; Ohno S.; Segal G.M.; Fanning S.; Zimmermann J.; Lydon N.B.; Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells. Nat Med  1996,2(5),561-566","journal-title":"Nat Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/ph15030309","volume":"15","author":"Santos C.","year":"2022","unstructured":"Santos C.; Pimentel L.; Canzian H.; Oliveira A.; Junior F.; Dantas R.; Hoelz L.; Marinho D.; Cunha A.; Bastos M.; Boechat N.; Hybrids of imatinib with quinoline: Synthesis, antimyeloproliferative activity evaluation, and molecular docking. Pharmaceuticals (Basel)  2022,15(3),309","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"Braun T.P.","year":"2020","unstructured":"Braun T.P.; Eide C.A.; Druker B.J.; Response and resistance to Bcr-Abl1-targeted therapies. Cancer Cell  2020,37(4),530-542","journal-title":"Cancer Cell"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s12185-021-03126-6","volume":"113","author":"Lee H.","year":"2021","unstructured":"Lee H.; Basso I.N.; Kim D.D.H.; Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Hematol  2021,113(5),632-641","journal-title":"Int J Hematol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.3390\/cancers13205116","volume":"13","author":"Ono T.","year":"2021","unstructured":"Ono T.; Which tyrosine kinase inhibitors should be selected as the first-line treatment for chronic myelogenous leukemia in chronic phase? Cancers (Basel)  2021,13(20),5116","journal-title":"Cancers (Basel)"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"9774","DOI":"10.1080\/07391102.2021.1935320","volume":"40","author":"Pereira W.A.","year":"2022","unstructured":"Pereira W.A.; Nascimento \u00c9.C.M.; Martins J.B.L.; Electronic and structural study of T315I mutated form in DFG-out conformation of BCR-ABL inhibitors. J Biomol Struct Dyn  2022,40(20),9774-9788","journal-title":"J Biomol Struct Dyn"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","volume":"11","author":"Rossari F.","year":"2018","unstructured":"Rossari F.; Minutolo F.; Orciuolo E.; Past, present, and future of Bcr-Abl inhibitors: From chemical development to clinical efficacy. J Hematol Oncol  2018,11(1),84","journal-title":"J Hematol Oncol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"106678","DOI":"10.1016\/j.ejps.2023.106678","volume":"193","author":"Sun L.","year":"2024","unstructured":"Sun L.; Yang P.C.; Luan L.; Sun J.F.; Wang Y.T.; Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignancies. Eur J Pharm Sci  2024,193,106678","journal-title":"Eur J Pharm Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/9783527824595","author":"Alza E.","year":"2022","unstructured":"Alza E.;  Flow and Microreactor Technology in Medicinal Chemistry  2022,154-103","journal-title":"Flow and Microreactor Technology in Medicinal Chemistry"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"Druker B.J.","year":"2006","unstructured":"Druker B.J.; Guilhot F.; O\u2019Brien S.G.; Gathmann I.; Kantarjian H.; Gattermann N.; Deininger M.W.N.; Silver R.T.; Goldman J.M.; Stone R.M.; Cervantes F.; Hochhaus A.; Powell B.L.; Gabrilove J.L.; Rousselot P.; Reiffers J.; Cornelissen J.J.; Hughes T.; Agis H.; Fischer T.; Verhoef G.; Shepherd J.; Saglio G.; Gratwohl A.; Nielsen J.L.; Radich J.P.; Simonsson B.; Taylor K.; Baccarani M.; So C.; Letvak L.; Larson R.A.; Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med  2006,355(23),2408-2417","journal-title":"N Engl J Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/1947601912462126","volume":"3","author":"Reddy E.P.","year":"2012","unstructured":"Reddy E.P.; Aggarwal A.K.; The ins and outs of Bcr-Abl inhibition. Genes Cancer  2012,3(5-6),447-454","journal-title":"Genes Cancer"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","volume":"13","author":"Senapati J.","year":"2023","unstructured":"Senapati J.; Sasaki K.; Issa G.C.; Lipton J.H.; Radich J.P.; Jabbour E.; Kantarjian H.M.; Management of chronic myeloid leukemia in 2023 \u2013 common ground and common sense. Blood Cancer J  2023,13(1),58","journal-title":"Blood Cancer J"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","volume":"98","author":"Nicolini F.E.","year":"2013","unstructured":"Nicolini F.E.; Ibrahim A.R.; Soverini S.; Martinelli G.; M\u00fcller M.C.; Hochhaus A.; Dufva I.H.; Kim D.W.; Cortes J.; Mauro M.J.; Chuah C.; Labussi\u00e8re H.; Morisset S.; Roche-Lestienne C.; Lippert E.; Hayette S.; Peter S.; Zhou W.; Maguer-Satta V.; Michallet M.; Goldman J.; Apperley J.F.; Mahon F.X.; Marin D.; Etienne G.; The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica  2013,98(10),1510-1516","journal-title":"Haematologica"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"101196","DOI":"10.1016\/j.blre.2024.101196","volume":"65","author":"Wang Y.","year":"2024","unstructured":"Wang Y.; Liang Z.; Gale R.P.; Liao H.; Ma J.; Gong T.; Shao Y.; Liang Y.; Chronic myeloid leukaemia: Biology and therapy. Blood Rev  2024,65,101196","journal-title":"Blood Rev"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"106156","DOI":"10.1016\/j.phrs.2022.106156","volume":"178","author":"Roskoski R.","year":"2022","unstructured":"Roskoski R.; Jr Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia. Pharmacol Res  2022,178,106156","journal-title":"Pharmacol Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"Schoepfer J.","year":"2018","unstructured":"Schoepfer J.; Jahnke W.; Berellini G.; Buonamici S.; Cotesta S.; Cowan-Jacob S.W.; Dodd S.; Drueckes P.; Fabbro D.; Gabriel T.; Groell J.M.; Grotzfeld R.M.; Hassan A.Q.; Henry C.; Iyer V.; Jones D.; Lombardo F.; Loo A.; Manley P.W.; Pell\u00e9 X.; Rummel G.; Salem B.; Warmuth M.; Wylie A.A.; Zoller T.; Marzinzik A.L.; Furet P.; Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem  2018,61(18),8120-8135","journal-title":"J Med Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","volume":"15","author":"Jiang Q.","year":"2022","unstructured":"Jiang Q.; Li Z.; Qin Y.; Li W.; Xu N.; Liu B.; Zhang Y.; Meng L.; Zhu H.; Du X.; Chen S.; Liang Y.; Hu Y.; Liu X.; Song Y.; Men L.; Chen Z.; Niu Q.; Wang H.; Lu M.; Yang D.; Zhai Y.; Huang X.; Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: Results of an open-label, multicenter phase 1\/2 trial. J Hematol Oncol  2022,15(1),113","journal-title":"J Hematol Oncol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1021\/jm301581y","volume":"56","author":"Ren X.","year":"2013","unstructured":"Ren X.; Pan X.; Zhang Z.; Wang D.; Lu X.; Li Y.; Wen D.; Long H.; Luo J.; Feng Y.; Zhuang X.; Zhang F.; Liu J.; Leng F.; Lang X.; Bai Y.; She M.; Tu Z.; Pan J.; Ding K.; Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem  2013,56(3),879-894","journal-title":"J Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","volume":"15","author":"Milojkovic D.","year":"2009","unstructured":"Milojkovic D.; Apperley J.; Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res  2009,15(24),7519-7527","journal-title":"Clin Cancer Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1080\/07391102.2022.2062784","volume":"41","author":"Koroleva E.V.","year":"2023","unstructured":"Koroleva E.V.; Kornoushenko Y.V.; Karpenko A.D.; Bosko I.P.; Siniutsich J.V.; Ignatovich Z.V.; Andrianov A.M.; In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: Application for the native and mutant (T315I) Bcr-Abl tyrosine kinase. J Biomol Struct Dyn  2023,41(9),4065-4080","journal-title":"J Biomol Struct Dyn"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1134\/S1068162020020089","volume":"46","author":"Fedarkevich A.N.","year":"2020","unstructured":"Fedarkevich A.N.; Sharko O.L.; Shmanai V.V.; Computer modeling and synthesis of potential \u0131nhibitors of tyrosine kinase Bcr-Abl with the T315I mutation. Russ J Bioorganic Chem  2020,46(2),187-198","journal-title":"Russ J Bioorganic Chem"},{"key":"ref=35","first-page":"102","volume":"46","author":"G\u00fcnay F.","year":"2022","unstructured":"G\u00fcnay F.; Balta S.; Synthesis, molecular modeling, and biological evaluation of novel imatinib derivatives asanticancer agents. Turk J Chem  2022,46(1),102-186","journal-title":"Turk J Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"103904","DOI":"10.1016\/j.drudis.2024.103904","volume":"29","author":"Maddeboina K.","year":"2024","unstructured":"Maddeboina K.; Yada B.; Kumari S.; McHale C.; Pal D.; Durden D.L.; Recent advances in multitarget-directed ligands via in silico drug discovery. Drug Discov Today  2024,29(3),103904","journal-title":"Drug Discov Today"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"10898","DOI":"10.1021\/acs.jmedchem.1c01853","volume":"65","author":"Pandrala M.","year":"2022","unstructured":"Pandrala M.; Bruyneel A.A.N.; Hnatiuk A.P.; Mercola M.; Malhotra S.V.; Designing novel Bcr-Abl inhibitors for chronic myeloid leukemia with improved cardiac safety. J Med Chem  2022,65(16),10898-10919","journal-title":"J Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.canlet.2019.11.040","volume":"472","author":"Gupta P.","year":"2020","unstructured":"Gupta P.; Zhang G.N.; Barbuti A.M.; Zhang X.; Karadkhelkar N.; Zhou J.; Ding K.; Pan J.; Yoganathan S.; Yang D.H.; Chen Z.S.; Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. Cancer Lett  2020,472,132-141","journal-title":"Cancer Lett"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"10407","DOI":"10.18632\/oncotarget.2090","volume":"5","author":"Shen Y.","year":"2014","unstructured":"Shen Y.; Ren X.; Ding K.; Zhang Z.; Wang D.; Pan J.; Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFR\u03b1-expressing cells. Oncotarget  2014,5(21),10407-10420","journal-title":"Oncotarget"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"112710","DOI":"10.1016\/j.ejmech.2020.112710","volume":"207","author":"El-Damasy A.K.","year":"2020","unstructured":"El-Damasy A.K.; Jin H.; Seo S.H.; Bang E.K.; Keum G.; Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity. Eur J Med Chem  2020,207,112710","journal-title":"Eur J Med Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"7434","DOI":"10.1021\/acs.jmedchem.1c00082","volume":"64","author":"Zhang D.","year":"2021","unstructured":"Zhang D.; Li P.; Gao Y.; Song Y.; Zhu Y.; Su H.; Yang B.; Li L.; Li G.; Gong N.; Lu Y.; Shao H.; Yu C.; Huang H.; Discovery of a candidate containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden scaffold as a highly potent pan-inhibitor of the Bcr-Abl kinase including the T315I-resistant mutant for the treatment of chronic myeloid leukemia. J Med Chem  2021,64(11),7434-7452","journal-title":"J Med Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"130502","DOI":"10.1016\/j.molstruc.2021.130502","volume":"1239","author":"Kantankar A.","year":"2021","unstructured":"Kantankar A.; Jayaprakash Rao Y.; Mallikarjun G.; Hemasri Y.; Kethiri R.R.; Rational design, synthesis, biological evaluation and molecular docking studies of chromone-pyrimidine derivatives as potent anti-cancer agents. J Mol Struct  2021,1239,130502","journal-title":"J Mol Struct"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"103054","DOI":"10.1016\/j.arabjc.2021.103054","volume":"14","author":"Munikrishnappa C.S.","year":"2021","unstructured":"Munikrishnappa C.S.; Suresh Kumar G.V.; Bhandare R.R.; Shaik A.B.; Design, synthesis, and biological evaluation of novel bromo-pyrimidine analogues as tyrosine kinase inhibitors. Arab J Chem  2021,14(4),103054","journal-title":"Arab J Chem"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3762\/bjoc.17.144","volume":"17","author":"Pimentel L.C.F.","year":"2021","unstructured":"Pimentel L.C.F.; Hoelz L.V.B.; Canzian H.F.; (Phenylamino)pyrimidine-1,2,3-triazole derivatives as analogs of imatinib: Searching for novel compounds against chronic myeloid leukemia. Beilstein J Org Chem  2021,17,2260-2269","journal-title":"Beilstein J Org Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00044-020-02656-8","volume":"30","author":"Abdellatif K.R.A.","year":"2021","unstructured":"Abdellatif K.R.A.; Bakr R.B.; Pyrimidine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment. Med Chem Res  2021,30(1),31-49","journal-title":"Med Chem Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1021\/jm400233w","volume":"56","author":"Radi M.","year":"2013","unstructured":"Radi M.; Tintori C.; Musumeci F.; Brullo C.; Zamperini C.; Dreassi E.; Fallacara A.L.; Vignaroli G.; Crespan E.; Zanoli S.; Laurenzana I.; Filippi I.; Maga G.; Schenone S.; Angelucci A.; Botta M.; Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant. J Med Chem  2013,56(13),5382-5394","journal-title":"J Med Chem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"106071","DOI":"10.1016\/j.bioorg.2022.106071","volume":"128","author":"Di Maria S.","year":"2022","unstructured":"Di Maria S.; Picarazzi F.; Mori M.; Cianciusi A.; Carbone A.; Crespan E.; Perini C.; Sabetta S.; Deplano S.; Poggialini F.; Molinari A.; Aronne R.; Maccioni E.; Maga G.; Angelucci A.; Schenone S.; Musumeci F.; Dreassi E.; Novel pyrazolo[3,4-d]pyrimidines as dual Src\/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment. Bioorg Chem  2022,128,106071","journal-title":"Bioorg Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1021\/acs.jcim.6b00138","volume":"57","author":"Dolatkhah Z.","year":"2017","unstructured":"Dolatkhah Z.; Javanshir S.; Sadr A.S.; Hosseini J.; Sardari S.; Synthesis, molecular docking, molecular dynamics studies, and biological evaluation of 4h-chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate derivatives as potential antileukemic agents. J Chem Inf Model  2017,57(6),1246-1257","journal-title":"J Chem Inf Model"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"5830","DOI":"10.1016\/j.bmcl.2016.10.007","volume":"26","author":"Hu L.","year":"2016","unstructured":"Hu L.; Cao T.; Lv Y.; Ding Y.; Yang L.; Zhang Q.; Guo M.; Design, synthesis, and biological activity of 4-(imidazo[1,2- b]pyridazin-3-yl)-1 H -pyrazol-1-yl-phenylbenzamide derivatives as BCR\u2013ABL kinase inhibitors. Bioorg Med Chem Lett  2016,26(23),5830-5835","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2201410","DOI":"10.1080\/14756366.2023.2201410","volume":"38","author":"Malarz K.","year":"2023","unstructured":"Malarz K.; Mularski J.; Pacholczyk M.; Musiol R.; Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations. J Enzyme Inhib Med Chem  2023,38(1),2201410","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"116398","DOI":"10.1016\/j.bmc.2021.116398","volume":"48","author":"Pan X.","year":"2021","unstructured":"Pan X.; Liu N.; Zhang Q.; Wang K.; Li Y.; Shan Y.; Li Z.; Zhang J.; Design, synthesis, and biological evaluation of novel Bcr-AblT315I inhibitors incorporating amino acids as flexible linker. Bioorg Med Chem  2021,48,116398","journal-title":"Bioorg Med Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"129144","DOI":"10.1016\/j.bmcl.2023.129144","volume":"81","author":"Wang X.","year":"2023","unstructured":"Wang X.; Xu Z.; Feng J.; Pan G.; He X.; Lv M.; Chen H.; Jiang W.; Ji J.; Yang M.; Synthesis and biological evaluation of novel aromatic amide derivatives as potential BCR-ABL inhibitors. Bioorg Med Chem Lett  2023,81,129144","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"135154","DOI":"10.1016\/j.molstruc.2023.135154","volume":"1282","author":"Wang X.J.","year":"2023","unstructured":"Wang X.J.; Pan G.; Zhang Z.; Feng J.; Xu Z.; Zheng L.; Ma S.; Dong G-S.; Hou X.; Deng Y-M.; Ji J.; Yang M.; Design, synthesis and antitumor evaluation of 3 chloro-4 - (pyridin-2-ylmethoxy) aniline derivatives as BCR-ABL kinase. J Mol Struct  2023,1282,135154","journal-title":"J Mol Struct"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"114425","DOI":"10.1016\/j.ejmech.2022.114425","volume":"238","author":"Pan X.","year":"2022","unstructured":"Pan X.; Liu N.; Liu Y.; Zhang Q.; Wang K.; Liu X.; Zhang J.; Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors. Eur J Med Chem  2022,238,114425","journal-title":"Eur J Med Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"e202203878","DOI":"10.1002\/anie.202203878","volume":"61","author":"Chen P.","year":"2022","unstructured":"Chen P.; Sun J.; Zhu C.; Tang G.; Wang W.; Xu M.; Xiang M.; Zhang C.J.; Zhang Z.M.; Gao L.; Yao S.Q.; Cell-active, reversible, and irreversible covalent inhibitors that selectively target the catalytic lysine of Bcr-Abl kinase. Angew Chem Int Ed  2022,61(26),e202203878","journal-title":"Angew Chem Int Ed"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"115687","DOI":"10.1016\/j.ejmech.2023.115687","volume":"259","author":"Ning C.","year":"2023","unstructured":"Ning C.; Tao A.; Xu J.; Design, synthesis, and biological evaluation of 3, 5-disubsituted-1H-pyrazolo[3,4-b]pyridines as multiacting inhibitors against microtubule and kinases. Eur J Med Chem  2023,259,115687","journal-title":"Eur J Med Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3390\/pharmaceutics14061294","volume":"14","author":"Bertrand J.","year":"2022","unstructured":"Bertrand J.; Dost\u00e1lov\u00e1 H.; Kry\u0161tof V.; Jorda R.; Delgado T.; Castro-Alvarez A.; Mella J.; Cabezas D.; Fa\u00fandez M.; Espinosa-Bustos C.; Salas C.O.; Design, synthesis, in silico studies and inhibitory activity towards Bcr-Abl, BTK and FLT3-ITD of new2,6,9-trisubstituted purine derivatives as potential agents for the treatment of leukemia. Pharmaceutics  2022,14(6),1294","journal-title":"Pharmaceutics"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"103361","DOI":"10.1016\/j.bioorg.2019.103361","volume":"94","author":"Bertrand J.","year":"2020","unstructured":"Bertrand J.; Dost\u00e1lov\u00e1 H.; Krystof V.; Jorda R.; Castro A.; Mella J.; Espinosa-Bustos C.; Mar\u00eda Zarate A.; Salas C.O.; New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia. Bioorg Chem  2020,94,103361","journal-title":"Bioorg Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/fcp.12540","volume":"34","author":"de Oliveira Ribeiro H.","year":"2020","unstructured":"de Oliveira Ribeiro H.; Cortez A.P.; de \u00c1vila R.I.; da Silva A.C.G.; de Carvalho F.S.; Menegatti R.; Li\u00e3o L.M.; Valadares M.C.; Small\u2010molecule MDM2 inhibitor LQFM030\u2010induced apoptosis in p53\u2010null K562 chronic myeloid leukemia cells. Fundam Clin Pharmacol  2020,34(4),444-457","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"113645","DOI":"10.1016\/j.ejmech.2021.113645","volume":"223","author":"Liu H.","year":"2021","unstructured":"Liu H.; Ding X.; Liu L.; Mi Q.; Zhao Q.; Shao Y.; Ren C.; Chen J.; Kong Y.; Qiu X.; Elvassore N.; Yang X.; Yin Q.; Jiang B.; Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation. Eur J Med Chem  2021,223,113645","journal-title":"Eur J Med Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.apsb.2020.11.009","volume":"11","author":"Jiang L.","year":"2021","unstructured":"Jiang L.; Wang Y.; Li Q.; Tu Z.; Zhu S.; Tu S.; Zhang Z.; Ding K.; Lu X.; Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation. Acta Pharm Sin B  2021,11(5),1315-1328","journal-title":"Acta Pharm Sin B"},{"key":"ref=62","first-page":"2018","volume":"8","author":"Rojas-Vargas J.A.","year":"2019","unstructured":"Rojas-Vargas J.A.; Garc\u00eda-L\u00f3pez A.; Rodr\u00edguez L.; Froeyen M.; Molecular docking studies of arylsubstituted imidazoles on oncogenic protein Bcr-Abl tyrosine kinase 1 1 1 2. PharmaSciTech  2019,8(2),2018","journal-title":"PharmaSciTech"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/cbdd.14343","volume":"102","author":"Hekmatshoar Y.","year":"2023","unstructured":"Hekmatshoar Y.; Ozkan T.; Alp M.; Gurkan-Alp A.S.; Sunguroglu A.; Some 2\u2010[4\u2010(1H\u2010benzimidazol\u20101\u2010yl)phenyl]\u20101H\u2010benzimidazole derivatives overcome imatinib resistance by induction of apoptosis and reduction of P\u2010glycoprotein activity. Chem Biol Drug Des  2023,102(6),1521-1533","journal-title":"Chem Biol Drug Des"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"115610","DOI":"10.1016\/j.ejmech.2023.115610","volume":"258","author":"Shaldam M.A.","year":"2023","unstructured":"Shaldam M.A.; Hendrychov\u00e1 D.; El-Haggar R.; Voj\u00e1\u010dkov\u00e1 V.; Majrashi T.A.; Elkaeed E.B.; Masurier N.; Kry\u0161tof V.; Tawfik H.O.; Eldehna W.M.; 2,4-Diaryl-pyrimido[1,2-a]benzimidazole derivatives as novel anticancer agents endowed with potent anti-leukemia activity: Synthesis, biological evaluation and kinase profiling. Eur J Med Chem  2023,258,115610","journal-title":"Eur J Med Chem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.3390\/molecules28145359","volume":"28","author":"Nitulescu G.M.","year":"2023","unstructured":"Nitulescu G.M.; Stancov G.; Seremet O.C.; Nitulescu G.; Mihai D.P.; Duta-Bratu C.G.; Barbuceanu S.F.; Olaru O.T.; The importance of the pyrazole scaffold in the design of protein kinases inhibitors as targeted anticancer therapies. Molecules  2023,28(14),5359","journal-title":"Molecules"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3390\/molecules27010330","volume":"27","author":"El-Gamal M.I.","year":"2022","unstructured":"El-Gamal M.I.; Zaraei S.O.; Madkour M.M.; Anbar H.S.; Evaluation of substituted pyrazole-based kinase inhibitors in one decade (2011\u20132020): Current status and future prospects. Molecules  2022,27(1),330","journal-title":"Molecules"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"130345","DOI":"10.1016\/j.molstruc.2021.130345","volume":"1237","author":"Abu-Safieh K.","year":"2021","unstructured":"Abu-Safieh K.; El-Barghouthi M.I.; Khanfar M.A.; Salameh B.A.; Al-Aqrabawi I.S.; Hourani B.J.A.; Ali B.F.; Crystal structure of 1-(1,3-dimethyl-4-nitro-1H-pyrazol-5-yl)-3,5-diphenyl-1H-pyrazole and molecular docking studies of 1-(1,3-dimethyl-4-nitro-1H-pyrazol-5-yl)-3,5-diphenyl-1H-pyrazole and 5-methyl-1-(1,3-dimethyl-4-nitro-1H-pyrazol-5-yl)-3-phenyl-1H-pyrazole towards tyrosine kinases. J Mol Struct  2021,1237,130345","journal-title":"J Mol Struct"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"e0236839","DOI":"10.1371\/journal.pone.0236839","volume":"15","author":"Lewis T.R.","year":"2020","unstructured":"Lewis T.R.; Smith J.; Griffin K.; Aguiar S.; Rueb K.F.; Holmberg-Douglas N.; Sampson E.M.; Tomasetti S.; Rodriguez S.; Stachura D.L.; Arpin C.C.; NHD2-15, a novel antagonist of growth factor receptor-bound protein-2 (GRB2), inhibits leukemic proliferation. PLoS One  2020,15(8),e0236839","journal-title":"PLoS One"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"103055","DOI":"10.1016\/j.bioorg.2019.103055","volume":"90","author":"Rezaei Z.","year":"2019","unstructured":"Rezaei Z.; Didehvar M.; Mahdavi M.; Azizian H.; Hamedifar H.; Mohammed E.H.M.; Ostad S.; Amini M.; Anticancer properties of N-alkyl-2, 4-diphenylimidazo [1, 2-a] quinoxalin-1-amine derivatives; kinase inhibitors. Bioorg Chem  2019,90,103055","journal-title":"Bioorg Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.3390\/molecules26154599","volume":"26","author":"Ahmadu A.A.","year":"2021","unstructured":"Ahmadu A.A.; Delehouz\u00e9 C.; Haruna A.; Mustapha L.; Lawal B.A.; Udobre A.; Baratte B.; Triscornia C.; Autret A.; Robert T.; Bulinski J.C.; Rousselot M.; Simoes Eug\u00e9nio M.; Dimanche-Boitrel M.T.; Petzer J.P.; Legoabe L.J.; Bach S.; Betulin, a newly characterized compound in Acacia auriculiformis bark, is a multi-target protein kinase inhibitor. Molecules  2021,26(15),4599","journal-title":"Molecules"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"109535","DOI":"10.1016\/j.cbi.2021.109535","volume":"344","author":"da Silva E.F.","year":"2021","unstructured":"da Silva E.F.; de Vargas A.S.; Willig J.B.; de Oliveira C.B.; Zimmer A.R.; Pilger D.A.; Buffon A.; Gnoatto S.C.B.; Synthesis and antileukemic activity of an ursolic acid derivative: A potential co-drug in combination with imatinib. Chem Biol Interact  2021,344,109535","journal-title":"Chem Biol Interact"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/mc.22321","volume":"55","author":"Zhao L.","year":"2016","unstructured":"Zhao L.; Miao H.C.; Li W.J.; Sun Y.; Huang S.; Li Z.Y.; Guo Q.L.; LW-213 induces G2\/M cell cycle arrest through AKT\/GSK3\u03b2\/\u03b2-catenin signaling pathway in human breast cancer cells. Mol Carcinog  2016,55(5),778-792","journal-title":"Mol Carcinog"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41401-019-0270-4","volume":"41","author":"Liu X.","year":"2020","unstructured":"Liu X.; Hu P.; Li H.; Yu X.; Wang X.; Qing Y.; Wang Z.; Wang H.; Zhu M.; Guo Q.; Hui H.; LW-213, a newly synthesized flavonoid, induces G2\/M phase arrest and apoptosis in chronic myeloid leukemia. Acta Pharmacol Sin  2020,41(2),249-259","journal-title":"Acta Pharmacol Sin"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1021\/jm301891t","volume":"56","author":"Hong S.","year":"2013","unstructured":"Hong S.; Kim J.; Yun S.M.; Lee H.; Park Y.; Hong S.S.; Hong S.; Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant. J Med Chem  2013,56(9),3531-3545","journal-title":"J Med Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"103255","DOI":"10.1016\/j.bioorg.2019.103255","volume":"92","author":"Bayrak N.","year":"2019","unstructured":"Bayrak N.; Y\u0131ld\u0131r\u0131m H.; Y\u0131ld\u0131z M.; Radwan M.O.; Otsuka M.; Fujita M.; Tuyun A.F.; Ciftci H.I.; Design, synthesis, and biological activity of Plastoquinone analogs as a new class of anticancer agents. Bioorg Chem  2019,92,103255","journal-title":"Bioorg Chem"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115734064311341240929175508","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/235099\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115734064311341240929175508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:42:00Z","timestamp":1759995720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/235099\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":75,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115734064311341240929175508","relation":{},"ISSN":["1573-4064"],"issn-type":[{"type":"print","value":"1573-4064"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}